

## CLAIM AMENDMENTS

Claims 1 through 19 (canceled).

1           Claim 20 (new) Recombinant poxvirus comprising in the  
2   viral genome at least two expression cassettes, each comprising the  
3   cowpox ATI promoter or a derivative thereof or a subsequence of the  
4   ATI promoter or the derivative thereof and a coding sequence,  
5   wherein the expression of the coding sequence is regulated by said  
6   promoter, derivative or subsequence and wherein the derivative of  
7   the cowpox ATI promoter is a sequence that has a homology of at  
8   least 60% when compared to the sequence of SEQ ID.: No. 1 and/or a  
9   sequence in which not more than 6 nucleotides are substituted,  
10   deleted and/or inserted in the sequence of SEQ ID.: No. 1, wherein  
11   the subsequence of the ATI promoter has a length of at least 10  
12   nucleotides of the sequence of SEQ ID.: No. 1 and wherein the  
13   promoter, derivative or subsequence has the biological activity of  
14   being active as a promoter.

1           Claim 21 (new) Recombinant poxvirus according to claim  
2   20, wherein the promoter, derivative or subsequence has the  
3   biological activity of being active as a Vaccinia virus late  
4   promoter.

1           Claim 22 (new) Recombinant poxvirus according to claim  
2   20, wherein the promoter, derivative or subsequence comprises  
3   nucleotides 25 to 29 or 22 to 29 of SEQ ID.: No. 1.

1           Claim 23 (new) Recombinant poxvirus according to claim  
2   20, wherein the promoters, derivatives or subsequences in the  
3   recombinant poxvirus are the same.

1           Claim 24 (new) Recombinant poxvirus according to claim  
2   20, wherein at least two expression cassettes are inserted into the  
3   same insertion site in the poxvirus genome.

1           Claim 25 (new) Recombinant poxvirus according to claim  
2   20, wherein the promoter in at least one of the expression  
3   cassettes has the sequence of SEQ ID.: No. 1.

1           Claim 26 (new) Recombinant poxvirus according to claim  
2   20, wherein the promoter in at least one of the expression  
3   cassettes is a derivative of the ATI promoter or a subsequence of  
4   the ATI promoter or a derivative thereof.

1           Claim 27 (new) Recombinant poxvirus according to claim  
2   20, wherein the poxvirus is selected from the group consisting of  
3   orthopoxviruses and avipoxviruses.

1           Claim 28 (new) Recombinant poxvirus according to claim  
2   27, wherein the orthopoxvirus is a vaccinia virus and wherein the  
3   avipoxvirus is selected from the group consisting of canarypoxvirus  
4   and fowlpoxvirus.

1           Claim 29 (new) Recombinant poxvirus according to claim  
2   28, wherein the vaccinia virus is modified vaccinia virus strain  
3   Ankara (MVA), in particular MVA-BN and MVA 575, deposited under  
4   numbers V00083008 and V00120707, respectively, at the European  
5   Collection of Animal Cell Cultures (ECACC).

1           Claim 30 (new) Recombinant poxvirus according to claim  
2   29, wherein at least one of the expression cassettes is inserted in  
3   a naturally occurring deletion site of the MVA genome with respect  
4   to the genome of the vaccinia virus strain Copenhagen.

1           Claim 31 (new) Recombinant poxvirus according to claim  
2   20, wherein at least one of the expression cassettes is inserted in  
3   an intergenic region of the poxvirus genome.

1           Claim 32 (new) Recombinant poxvirus according to claim  
2   20, wherein at least one of the coding sequences codes for at least  
3   one antigen, antigenic epitope, and/or a therapeutic compound.

1           Claim 33 (new) Recombinant poxvirus according to claim 20  
2   as vaccine or medicament.

1           Claim 34 (new) Vaccine or pharmaceutical composition  
2   comprising a recombinant poxvirus according to claim 20.

1           Claim 35 (new) Use of the recombinant poxvirus according  
2   to claim 20 for the preparation of a vaccine or medicament.

1           Claim 36 (new) Method for introducing coding sequences  
2   into target cells comprising the infection of the target cells with  
3   the virus according to claim 20.

1           Claim 37 (new) Method for producing a peptide, protein  
2   and/or virus comprising:

3           a) infection of a host cell with the recombinant poxvirus  
4   according to claim 20,

5           b) cultivation of the infected host cell under suitable  
6   conditions, and

7           c) isolation and/or enrichment of the peptide and/or  
8   protein and/or viruses produced by said host cell.

1           Claim 38 (new) Method for effecting an immunological  
2 response in a living animal host including a human comprising  
3 administering the virus according to claim 20 to the animal or  
4 human to be treated.

1           Claim 39 (new) Method according to claim 38 comprising  
2 the administration of at least  $10^2$  TCID<sub>50</sub> (tissue culture infectious  
3 dose) of the virus.

1           Claim 40 (new) A cell containing the virus according to  
2 claim 20.

1           Claim 41 (new) A method for the production of a  
2 recombinant virus according to claim 20 comprising the step of  
3 inserting at least two expression cassettes into the genome of a  
4 poxvirus.

1           Claim 42 (new) Method for effecting an immunological  
2 response in a living animal host, including a human, comprising  
3 administering the composition or vaccine according to claim 34 to  
4 the animal or human to be treated.